A team of scientists from the University of Oxford has found that after vaccination, Vaxzevria (formerly AstraZeneca Covid-19 vaccine) recipients were less likely to suffer portal vein thrombosis (PVT) – blood clots in the artery from the intestines to the liver.
For recipients of the viral vector Vaxzevria vaccine, the incidence rate for splanchnic thrombosis – clotting in the portal and other abdominal veins – is 1.6 per million people, according to data from the EU drugs regulator the European Medicines Agency (EMA). By contrast, some 44.9 cases of PVT per million people were seen among those who had been injected with the mRNA vaccines made by Moderna and Pfizer, the Oxford research, published on Thursday, said.
The risk of cerebral vein thrombosis, which caused many regulators to pause or discontinue using AstraZeneca’s and J&J vaccines, appears to be very similar for AstraZeneca’s vaccine (5 in a million) as for Pfizer’s and Moderna’s mRNA vaccines (4 in a million). pic.twitter.com/KZcMCIQVXd
— Sputnik V (@sputnikvaccine) April 16, 2021